Turning ideas into results
April 29, 2013

PREVENT signs an exclusive licensing agreement with Folia Biotech for the rights to use its proprietary PAL adjuvant technology to develop a vaccine against seasonal flu.

On April 10th, the Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a Canadian Centre of Excellence for Commercialization and Research (CECR) based at the University of Saskatchewan, announced it had signed an agreement that will accelerate the clinical development of Folia Biotech’s innovative adjuvant.

The PAL adjuvant system designed to enhance the immune response will be of considerable importance to people receiving a flu vaccine.

It is worth recalling that SOVAR had previously contributed $332,406 to support the development of one of Folia Biotech’s technologies.

For additional information, please read thepress release

About Folia Biotech
FOLIA BIOTECH is a biotechnology company founded by Dr. Denis Leclerc, a researcher at the Infectious Disease Research Centre (CRI) in Quebec City. The PAL technology that emerged from Dr. Leclerc’s work is based on the use of the recombinant protein of a plant virus (the papaya mosaic virus) as an adjuvant to enhance the immune response directed against the antigen or antigens within the vaccine. The PAL technology also constitutes a versatile vaccination platform enabling the development of innovative vaccines against any infectious disease. www.foliabiotech.com

The Pan-Provincial Vaccine Enterprise Inc. (PREVENT) is a not-for-profit organization incorporated as a commercial company whose mandate is to accelerate the development of promising vaccine candidates to meet existing or potential challenges to public health in Canada. The founding partners of PREVENT include the Vaccine and Infectious Disease Organization and International Vaccine Centre (VIDO-InterVac), the British Columbia Centre for Disease Control (BCCDC) and the Canadian Centre for Vaccinology (CCfV). By partnering with Canadian experts and shouldering the risk associated with the early stages of vaccine development, PREVENT strengthens the Canadian vaccine industry and fosters its growth, investments and international competitiveness.